Ann: AstraZeneca to use new ResApp software in clinical study, page-43

Maybe AstraZeneca couldn't spre a few bob to provide us some decent revenue :\ For me I can liken this annoucement to fairy floss, it's fluff (no real revenue) but pretty good fluff. Exactly like fairy floss.
We still need real commercialisation, real dollars. Going back to single digits IMO, in no time unless they can produce binding terms and $$ with an international mob.
Sentiment remains hold. Cap raise not yet required but not yet averted.